Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Biochemical Engineering >Inhibitors >protein tyrosine kinase >Palbociclib

Palbociclib

Palbociclib Structure
  • ₹10684.28 - ₹43061.85
  • Product name: Palbociclib
  • CAS: 571190-30-2
  • MF: C24H29N7O2
  • MW: 447.53
  • EINECS:810-186-2
  • MDL Number:MFCD11840850
  • Synonyms:PD 0332991;OTAVA-BB 1115529;Palbociclib;OTAVA-BB 1115529/PD0332991;Palbociclib(PD0332991);Palbociclib(free base);PALBOCICLIB PD 0332991;OTAVA-BB 1115529;API-Anti-Tumer;palbociclib (OTAVA-BB 1115529)
2 prices
Selected condition:

Brand

  • Sigma-Aldrich(India)

Package

  • 5MG
  • 25MG
  • ManufacturerSigma-Aldrich(India)
  • Product numberPZ0383
  • Product descriptionPalbociclib ≥98% (HPLC)
  • Packaging5MG
  • Price₹10684.28
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberPZ0383
  • Product descriptionPalbociclib ≥98% (HPLC)
  • Packaging25MG
  • Price₹43061.85
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
Sigma-Aldrich(India) PZ0383 Palbociclib ≥98% (HPLC) 5MG ₹10684.28 2022-06-14 Buy
Sigma-Aldrich(India) PZ0383 Palbociclib ≥98% (HPLC) 25MG ₹43061.85 2022-06-14 Buy

Properties

Melting point :200 ºC
Boiling point :711.5±70.0 °C(Predicted)
Density :1.313±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :Soluble in DMSO (up to 2 mg/ml with warming)
pka :8.66±0.10(Predicted)
form :powder
color :white to beige
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.

Safety Information

Symbol(GHS): GHS hazard pictogramsGHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H341 Suspected of causing genetic defects Germ cell mutagenicity Category 2 Warning P201,P202, P281, P308+P313, P405,P501
H373 May cause damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 2 Warning P260, P314, P501
H411 Toxic to aquatic life with long lasting effects Hazardous to the aquatic environment, long-term hazard Category 2
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313 IF exposed or concerned: Get medical advice/attention.

Description

Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) human epidural growth factor 2-negative (HER2-) metastatic breast cancer. It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women, or with fulvestrant in women with disease progression following hormonal therapy. Palbociclib was discovered at Warner- Lambert and developed by Pfizer after their merger. Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic.

Related product price